NCT02716233 - A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents | Biotech Hunter

Enrollment

2,044

Participants

Timeline

Start Date

September 19, 2016

Primary Completion Date

April 30, 2022

Study Completion Date

March 31, 2027

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG

pegaspargase 1250 IU/m2 x 2

only for ALL of standard risk and medium risk

DRUG

pegaspargase 2500 IU/m2 x 1

only for ALL of standard risk and medium risk

Trial Locations (28)

13385

CHU, Marseille

14033

CHU, Caen

21079

CHU, Dijon

25030

CHRU, Besançon

29609

CHU, Brest

31059

CHU, Toulouse

33076

CHU, Bordeaux

34295

CHU, Montpellier

35203

CHU, Rennes

37044

CHU, Tours

38043

CHU, Grenoble

42270

CHU, Saint-Etienne

44093

CHU, Nantes

49033

CHU, Angers

51100

CHU, Reims

54511

CHU, Nancy

59037

CHU, Lille

63003

CHU, Clermont-Ferrand

67098

CHU, Strasbourg

69373

Chu-Ihope, Lyon

75010

CHU Saint Louis, Paris

75012

CHU Armand Trousseau, Paris

75019

CHU Robert Debré, Paris

76031

CHU, Rouen

80054

CHU, Amiens

86000

CHU, Poitiers

87042

CHU, Limoges

06200

CHU, Nice